This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Hematology				
Familial hemophagocytic lymphohistiocytosis type 5	Syntaxin binding protein 2 (STXBP2; MUNC18-2)	Genetic studies in humans identified mutations in <i>STXBP2</i> that could be biomarkers of the hematological disorder familial hemophagocytic lymphohistiocytosis type 5. In six related families, eight patients with the disease had inherited mutations in <i>STXBP2</i> that were absent in healthy controls. Next steps could include studies to determine how the mutant variants contribute to disease pathophysiology.	Patent and licensing status unavailable	Côte, M. <i>et al. J. Clin. Invest.</i> ; published online Nov. 2, 2009; doi:10.1172/JCI40732 Contact: Geneviève de Saint Basile, Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France e-mail: genevieve.de-saint-basile@inserm.fr
		SciBX 2(45); doi:10.1038/scibx.2009.1665 Published online Nov. 19, 2009		